Morgan Stanley (MS) prospectus addendum supersedes earlier prospectuses for Series C
Rhea-AI Filing Summary
Morgan Stanley provides a prospectus addendum dated April 8, 2026 that supersedes earlier prospectuses when used for market-making transactions in its Global Medium-Term Notes, Series C and Global Units, Series C. The addendum directs readers to the applicable prospectus supplement or pricing supplement for specific terms.
Positive
- None.
Negative
- None.
Key Figures
Prospectus addendum date: April 8, 2026
1 metrics
Prospectus addendum date
April 8, 2026
Addendum supersedes earlier prospectuses when used for market-making
Key Terms
prospectus addendum, market-making transactions, prospectus supplement
3 terms
prospectus addendum regulatory
"Prospectus Addendum to the Prospectus dated April 8, 2026"
market-making transactions financial
"used in connection with market-making transactions of notes or units"
prospectus supplement regulatory
"read the terms of the accompanying prospectus supplement or pricing supplement"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does Morgan Stanley's April 8, 2026 prospectus addendum do (MS)?
It supersedes earlier prospectuses for market-making uses where referenced. The addendum states that the accompanying prospectus dated April 8, 2026 replaces any earlier prospectus for market-making transactions and directs readers to the prospectus supplement for specific note or unit terms.
Does the addendum change the specific terms of Series C notes or units (MS)?
No; it does not set specific terms itself. The addendum instructs readers to consult the applicable prospectus supplement or pricing supplement, which contains the specific terms and pricing for the offered notes or units.
Will proceeds or investor protections be affected by this prospectus addendum (MS)?
The addendum does not describe proceeds or new protections. It only clarifies which prospectus governs market-making transactions; specific cash-flow treatment and protections must be read in the prospectus supplement or pricing supplement.
Are the offered notes or units insured or bank obligations (MS)?
No. The addendum explicitly states the offered notes or units are not FDIC-insured and are not bank obligations or guaranteed by a bank. Investors should read the supplement for product-specific risk disclosures.
Who may use this prospectus addendum in market-making transactions (MS)?
Morgan Stanley & Co. LLC and certain Morgan Stanley affiliates may use it. The addendum says Morgan Stanley & Co. LLC will, and other Morgan Stanley affiliates may, use this prospectus addendum in connection with market-making transactions.
